in this issue
Regions :: North America :: U.S.
FDA issues warning letter to Sun Pharma's API plant in India
May 21, 2014 | Deepti Ramesh
FDA issued a warning letter on 7 May to the active pharmaceutical ingredient (API) and finished pharmaceutical manufacturing facilities of Sun Pharmaceutical Industries (Sun Pharma; Mumbai)—located at Karkhadi, Vadodara District, India—for violations of cGMP. The warning letter was published on the FDA Web site on 20 May. An FDA inspection from 13–16 November 2013 at the Karkhadi facility identified deviations from cGMP for the manufacture of APIs and the violation of cGMP regulations for finished pharmaceuticals, FDA says. An import alert was...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee